Biodesix (NASDAQ: BDSX) CCO details RSU vesting and tax-share sale

Rhea-AI Filing Summary

Biodesix Inc. Chief Commercial Officer Kieran O'Kane reported routine equity compensation activity. On January 15, 2026, 805 restricted stock units (RSUs) were converted into 805 shares of Common Stock at an exercise price of $0, reflecting prior awards adjusted for a one-for-twenty reverse stock split effective September 15, 2025. These RSUs are part of a grant that vests in four equal annual installments starting January 15, 2024, generally conditioned on continued service.

On January 16, 2026, 298 shares of Common Stock were sold at a weighted average price of $8.1493 per share, with prices ranging from $8.10 to $8.28, to cover taxes due upon RSU vesting. After these transactions, O'Kane directly held 7,869 shares of Common Stock and 1,609 RSUs.

Insider Trade Summary

Net Seller: 298 shares ($2,428)

Net Sell 3 txns

Insider O'Kane Kieran

Role Chief Commercial Officer

Sold 298 shs ($2K)

Type	Security	Shares	Price	Value
Sale	Common Stock	298	$8.1493	$2K
Exercise	Restricted Stock Units	805	$0.00	--
Exercise	Common Stock	805	$0.00	--

Holdings After Transaction: Common Stock — 7,869 shares (Direct); Restricted Stock Units — 1,609 shares (Direct)

Footnotes (1)

1. Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs. The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $8.10 to $8.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025. These RSUs vest in a series of four successive equal annual installments measured from January 15, 2024, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

O'Kane Kieran

(Last) (First) (Middle)

919 WEST DILLON RD

(Street)

LOUISVILLE CO 80027

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIODESIX INC [ BDSX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/15/2026		M		805	A	(1)	8,167	D
Common Stock	01/16/2026		S(2)		298	D	$8.1493(3)	7,869	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	01/15/2026		M			805(4)	(5)	(5)	Common Stock	805(4)	$0	1,609(4)	D

Explanation of Responses:

1. Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

2. These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.

3. The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $8.10 to $8.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025.

5. These RSUs vest in a series of four successive equal annual installments measured from January 15, 2024, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

	/s/ Robin H. Cowie as Attorney-in-Fact for Kieran O'Kane	01/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Biodesix (BDSX) report for Kieran O'Kane?

Biodesix reported that Chief Commercial Officer Kieran O'Kane had 805 RSUs convert into 805 shares of Common Stock on January 15, 2026, and then sold 298 shares of Common Stock on January 16, 2026.

At what price were Biodesix (BDSX) shares sold in this Form 4 filing?

The 298 shares of Common Stock were sold at a weighted average price of $8.1493 per share, in multiple trades between $8.10 and $8.28, to cover taxes upon RSU vesting.

How many Biodesix (BDSX) shares and RSUs does Kieran O'Kane hold after these transactions?

Following the reported transactions, Kieran O'Kane directly held 7,869 shares of Biodesix Common Stock and 1,609 restricted stock units.

What are the key terms of Kieran O'Kane's Biodesix (BDSX) RSU award?

The RSUs represent the right to receive one share of Biodesix Common Stock per unit. They vest in four successive equal annual installments starting on January 15, 2024, generally subject to O'Kane's continued service, and have no expiration date.

How did Biodesix's reverse stock split affect the RSU and share amounts in this Form 4?

The filing notes that the reported RSU and share numbers were adjusted for a one-for-twenty reverse stock split that became effective on September 15, 2025.

Why were some Biodesix (BDSX) shares sold in this insider transaction?

The filing states that the 298 shares of Common Stock were sold automatically by the issuer's broker to cover taxes due upon the vesting of RSUs for certain employees, including Kieran O'Kane.